Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
- DOI
- 10.1016/j.oraloncology.2016.09.009
- Published
- 2016 Nov
- Container
- Oral oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.oraloncology.2016.09.009,
title = {Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.},
author = {Del Barco Morillo E and Mesía R and Adansa Klain JC and Vázquez Fernández S and Martínez-Galán J and Pastor Borgoñon M and González-Rivas C and Caballero Daroqui J and Berrocal A and Martínez-Trufero J and Vera R and Cruz-Hernández JJ and Spanish Head And Neck Cancer Cooperative Group (TTCC)},
year = {2016},
journal = {Oral oncology},
doi = {10.1016/j.oraloncology.2016.09.009},
url = {https://doi.org/10.1016/j.oraloncology.2016.09.009}
}RIS
TY - JOUR TI - Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. AU - Del Barco Morillo E AU - Mesía R AU - Adansa Klain JC AU - Vázquez Fernández S AU - Martínez-Galán J AU - Pastor Borgoñon M AU - González-Rivas C AU - Caballero Daroqui J AU - Berrocal A AU - Martínez-Trufero J AU - Vera R AU - Cruz-Hernández JJ AU - Spanish Head And Neck Cancer Cooperative Group (TTCC) PY - 2016 JO - Oral oncology DO - 10.1016/j.oraloncology.2016.09.009 UR - https://doi.org/10.1016/j.oraloncology.2016.09.009 ER -
APA
E, D. B. M., R, M., JC, A. K., S, V. F., J, M., M, P. B., C, G., J, C. D., A, B., J, M., R, V., JJ, C., & (TTCC), S. H. A. N. C. C. G. (2016). Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.. Oral oncology. https://doi.org/10.1016/j.oraloncology.2016.09.009
Source records
- pubmed · retrieved 2026-09-27T00:46:26.572Z